Mechanistic insights into the transcription-mediated roles of non-coding RNAs in gene regulation.

Bioinformatics analysis of regulatory relationships between long non-coding RNA genes and transcription factor coding genes

Long non-coding RNAs (lncRNAs) are increasingly recognized as important regulators of gene expression, yet their interactions with transcription factors (TFs) remain poorly understood. While previous studies have identified lncRNA-TF associations in specific biological contexts, a broader perspective on their evolutionary and functional relationships remains necessary. In this study, we systematically analyze the proximity and co-expression patterns of lncRNAs and TF-encoding genes in humans. We reveal consistent spatial associations and tissue-specific co-expression between lncRNAs and TFs using genome-wide annotations and transcriptomic data. Time-series analysis reveals interesting, but not definitive, dynamic correlations suggesting potential functional interactions. Additionally, our evolutionary analysis identified conserved pairs across species, particularly those related to developmental processes such as eye development, highlighting possible avenues for further investigation in evolutionary and developmental contexts. In summary, our findings provide new insights into the spatial and co-expression associations between lncRNAs and TF genes, and suggest directions for future research on the potential roles of lncRNAs in gene regulatory networks.

Mechanisms of transcription termination across the coding and noncoding loci of the genome.

Bacterial small regulatory RNAs.

Transcriptional kinases drive gene expression network plasticity.

Eukaryotic transcription is a highly dynamic and adaptable process that underpins the gene expression programs regulating development, cellular identity, and responses to extracellular signals. Gene-specific regulation of transcription across different cell types and environmental conditions is therefore fundamental to both normal physiology and disease. This specificity is shaped by phosphorylation of the RNA polymerase II (RNAPII) C-terminal domain (CTD) and its associated transcription factors. While cyclin-dependent kinases (CDKs) have long been recognized as the regulators of RNAPII activity, emerging evidence points to a broader, more diverse network of transcriptional kinases. Here, we highlight non-canonical transcriptional kinases that could operate alongside and beyond CDKs to modulate transcription by RNAPII. We discuss how these kinases could introduce context-specific CTD modifications that enable transcriptional plasticity, facilitate rapid loci-specific activation, and integrate signaling and stress-responsive pathways, ultimately adding a layer of regulatory complexity with profound implications for dynamic transcriptional regulation in development, homeostasis, and disease.

Natural Antisense Transcripts in Human Gene Regulation and Disease: A Critical Appraisal of Mechanisms and Therapeutic Prospects

Natural antisense transcripts (NATs) are RNA molecules transcribed from the DNA strand opposite a protein-coding or non-coding gene, and they constitute one of the most pervasive yet mechanistically heterogeneous classes of the mammalian non-coding transcriptome. Since large-scale transcriptomic surveys demonstrated that a majority of transcriptional units in the human and mouse genomes are subject to antisense transcription, NATs have been implicated in transcriptional interference, chromatin remodelling through RNA:DNA triplex formation, microRNA sponging, modulation of mRNA stability, and direct control of translation initiation. This review critically synthesises the molecular evidence linking NATs to neurodegenerative, oncological and cardiovascular disease, with particular attention to BACE1-AS in Alzheimer's disease, HOTAIR in epithelial malignancies, and CDKN2B-AS1 (ANRIL) in atherosclerosis. Rather than treating this literature as a uniformly supportive body of evidence, the review foregrounds points of genuine scientific contention, including the divergence between cell-culture knockdown data and in vivo knockout phenotypes for HOTAIR, and the persistent difficulty of distinguishing cis-acting transcriptional interference from trans-acting RNA-mediated regulation. The therapeutic section evaluates antisense oligonucleotide strategies (AntagoNATs) and SINEUP-based translational enhancers as emerging modalities capable of achieving locus-specific, reversible upregulation of haploinsufficient genes, contrasting this mechanism with the predominantly inhibitory pharmacology of conventional oligonucleotide therapeutics. Methodological weaknesses recurring across the primary literature are assessed, including reliance on transformed cell lines, inconsistent knockdown efficiencies, sparse replication across independent laboratories, and limited attention to species-specific conservation of NAT sequences. The review concludes that while the mechanistic diversity of NAT-mediated regulation is now well established at the level of individual case studies, the field lacks generalisable rules predicting when a given antisense transcript will act in cis versus trans, and clinical translation remains constrained by delivery, tissue specificity and long-term safety considerations. Priorities for future research are identified, including standardised functional validation pipelines, comparative genomic conservation analyses, and controlled clinical evaluation of AntagoNAT and SINEUP platforms beyond monogenic haploinsufficiency disorders.

Functional genomics approaches for understanding the role of noncoding RNAS in human diseases

The latest functional genomics strategies used to examine NCRNAS are discussed and their transformative ability in accurate therapy is highlighted, highlighting their transformative ability in accurate therapy.